



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

**Summary for ARTG Entry:** 113926 OCTAGAM normal immunoglobulin (human) 2.5g/50mL injection bottle

**ARTG entry for** Medicine Registered  
**Sponsor** Octapharma Australia Pty Ltd  
**Postal Address** Jones Bay Wharf 42/26-32 Pirrama Road, PYRMONT, NSW, 2009  
Australia  
**ARTG Start Date** 16/11/2004  
**Product category** Medicine  
**Status** Active  
**Approval area** Drug Safety Evaluation Branch

### Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

### Products

#### 1. OCTAGAM normal immunoglobulin (human) 2.5g/50mL injection bottle

Product Type	Single Medicine Product	Effective date	8/10/2018
--------------	-------------------------	----------------	-----------

### Permitted Indications

#### Indication Requirements

No Indication Requirements included on Record

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

Replacement therapy: Primary immunodeficiency syndromes: congenital agammaglobulinaemia and hypogammaglobulinaemia; common variable immunodeficiency; severe combined immunodeficiencies; Wiskott Aldrich syndrome; Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. Children with congenital Acquired Immune Deficiency Syndrome (AIDS) who have repeated bacterial infections; Immunomodulatory effect: Idiopathic thrombocytopenic purpura, in adults or children with a high risk of bleeding or prior to surgery to correct platelet count. Guillain Barre syndrome. Kawasaki disease. Allogeneic bone marrow transplantation.

### Warnings

See Product Information and Consumer Medicine Information for this product

### Additional Product information

### Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	2 Years	Store below 25 degrees Celsius	Not recorded	Do not Freeze Protect from Light

### Pack Size/Poison information

#### Pack Size

50mL

#### Components

##### 1. Medicine Component

#### Dosage Form

#### Route of Administration

#### Visual Identification

#### Active Ingredients

human immunoglobulin G

#### Poison Schedule

(S4) Prescription Only Medicine

Injection

Intravenous

Clear or slightly opalescent solution.

50 mg/mL

Public Summary



**Australian Government**

**Department of Health**  
Therapeutic Goods Administration

---

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary